Evaluation of Cutaneous Modifications in Seventy-Seven Growth Hormone-Deficient ChildrenConte F.a,c · Diridollou S.c · Jouret B.b · Turlier V.c · Charveron M.c · Gall Y.c · Rochiccioli P.a,b · Bieth E.a,b · Tauber M.a,b
aCentre de Recherche sur la Croissance, Pavillon Leriche, Centre Hospitalier Universitaire de Purpan, Toulouse, and Pharmacia France, Guyancourt, France, and Pharmacia Sweden, Stockholm, Sweden; bEquipe d’Endocrinologie, Génétique et Gynécologie Médicale, Hôpital des Enfants, Toulouse, et cInstitut de Recherche Pierre-Fabre, Centre Jean-Louis-Alibert, Toulouse, France
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Cutaneous parameters such as dermal thickness, stiffness, elasticity, skin surface lipid and hydration were evaluated using noninvasive methods in 77 growth hormone-deficient (GHD) children before replacement therapy and in 70 non-GHD children. We showed that in GHD children, dermis was thinner (0.70 ± 0.10 vs. 0.80 ± 0.10 mm, p < 0.0001 for prepubertal children and 0.81 ± 0.10 vs. 0.94 ± 0.11 mm, p < 0.0001 for pubertal children), stiffer (178.5 ± 57.3 vs. 113.09 ± 37 kPa, p < 0.0001 for prepubertal children and 172.5 ± 61.7 vs. 117.3 ± 42.5 kPa for pubertal children, p < 0.001) and less elastic (0.44 ± 0.09 vs. 0.39 ± 0.06 (nonelasticity index), p < 0.01 for prepubertal children and 0.39 ± 0.05 vs. 0.33 ± 0.04, p < 0.001 for pubertal children) compared to controls. Fourteen GHD children were re-evaluated after 1 year of GH treatment: dermal thickness and skin stiffness were significantly improved (p < 0.001 and p < 0.05 respectively) while elasticity was not modified. During the same period, 11 controls did not show any significant cutaneous modification. IGF-1 values, but not IGFBP-3 values, correlated positively with dermal thickness in GHD children, before and after 1 year of GH treatment. To conclude, GHD children exhibited specific cutaneous modifications. In a subset of GHD children, we showed that these modifications were influenced by GH treatment. More extensive studies are needed to see if these changes correlated with other GH effects.
© 2001 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.